单位:[1]Capital Med Univ, Beijing Shijitan Hosp, Dept Breast Ctr, Beijing, Peoples R China[2]Capital Med Univ, Beijing Friendship Hosp, Med & Hlth Ctr, Beijing, Peoples R China首都医科大学附属北京友谊医院[3]Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Med Oncol, Los Angeles, CA 90095 USA[4]Liaoning Canc Hosp & Inst, Dept Internal Oncol, Shenyang, Liaoning, Peoples R China[5]China Japan Friendship Hosp, Dept Oncol, Beijing, Peoples R China[6]Shandong Canc Hosp, Dept Oncol, Jinan, Shandong, Peoples R China[7]Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China江苏省人民医院[8]Nanjing Med Univ, Jiangsu Canc Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China
第一作者单位:[1]Capital Med Univ, Beijing Shijitan Hosp, Dept Breast Ctr, Beijing, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Lv Shuzhen,Wang Yunchao,Sun Tao,et al.Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis (vol 41, pg 450, 2018)[J].ONCOLOGY RESEARCH and TREATMENT.2018,41(10):655-655.doi:10.1159/000492999.
APA:
Lv, Shuzhen,Wang, Yunchao,Sun, Tao,Wan, Donggui,Sheng, Lijun...&Li, Yanping.(2018).Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis (vol 41, pg 450, 2018).ONCOLOGY RESEARCH and TREATMENT,41,(10)
MLA:
Lv, Shuzhen,et al."Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis (vol 41, pg 450, 2018)".ONCOLOGY RESEARCH and TREATMENT 41..10(2018):655-655